SARS-CoV-2 Infection Elicits a Greater Humoral Immune Response in the Second Wave Than the First Wave

Purpose Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing pandemic of coronavirus disease 2019 (COVID-19). One year has passed since the rst COVID-19 case, and concerns have emerged regarding new variants, meaning that characterizing antibody-mediated immune response dynamics is of paramount importance. Here, we evaluated the humoral immune response against SARS-CoV-2 in subjects during the rst and second waves of the pandemic in Morocco. Methods We assessed humoral immune response in samples from 94 seropositive individuals in the rst wave (February to August 2020) and 596 seropositive individuals in the second wave (December 2020 to January 2021). Plasma samples were collected from volunteer blood donors and their levels of serum IgG to SARS-CoV-2 nucleoprotein (NP) were determined using architect SARS-CoV-2 IgG chemiluminescence microparticle immunoassay. Our results revealed an increase of humoral immunity during the second wave than rst wave (3.897 ± 0.079 vs. 2.842 ± 0.153, respectively, p<0.0001). Notably, we found an age-related gradient in antibody level, with higher antibody index in subjects at 45 years old and above (p= 0.01451). However, no signicant difference was found according to gender (p= 0.8629). Our highlighted an important issue regarding antibody-mediated immune against SARS-CoV-2 during the this might have due to the of different strains circulating during the

The North African kingdom of Morocco has adopted a range of measures to combat the COVID-19 pandemic, with surveillance for new variants including diagnostic and screening measures with nucleic acid ampli cation tests, antigen-based tests, serologic assays and genome sequencing among the approaches that have been applied. Previously, Morocco appeared to achieve a degree of control against the disease since the country 's Ministry of Health rst reported a case, on March 2nd, 2020. The   5,443,945 tests carried out in Morocco as of March 28th, 2021 yielded a total of 4 94, 659 positive  results, with 8,798 deaths and 482, 352 patients recorded as recovering from COVID-19. In January  28th, 2021, the kingdom launched the national vaccination campaign and as of March 28th, 2021, 4,302, 183 persons received their rst dose and 3,332, 292 second dose of a COVID-19 vaccine. As with many other countries, Morocco appears to have experienced waves of infection, with the rst wave regarded as commencing with the rst reported case in March 2020, and the second wave around September 2020, just weeks after the traditional Eid al-Adha festivities, which are marked by social and religious gatherings. The two waves are separated by a trough in daily recorded cases (Fig. 1). However, on January 18th, 2021, Morocco's health ministry con rmed its rst imported case of the UK variant, which was detected in the northern port of Tangier in a Moroccan national returning from Ireland via Marseille.
With recently described variants in SARS-CoV-2, and characterizing antibody (Ab)-mediated immune response dynamics of SARS-CoV-2 is fundamental to understand COVID-19 epidemiology, the path to protection against SARS-CoV-2 infection or re-infection, and for effective vaccine development [9]. Data of this nature are not yet available for SARS-CoV-2 infection. To investigate the humoral immune response against SARS-CoV-2 infection in the rst and second waves in Morocco, we subjected blood samples from donors who recovered from COVID-19 during the rst wave, or seroconverted during the second wave to a comparative evaluation.

Study participants
This is an observational study in healthy volunteers. We enrolled two groups of donors in two different periods, between 14th of February and 7th of August 202, for the rst wave), or 23th of December 2020 through January 8, 2021 (for the second wave). Blood donors satisfying the donation eligibility criteria set by the Moroccan Ministry of Health and testing positive for SARS-CoV-2 could be included in the study. Individuals underwent a health screening procedure before blood donation. All study participants provided written informed consent after they had been briefed on the purposes of the study. After enrolment, participants were grouped into three age categories: 18-25 years, 26-45 years and more than 45 years. The samples were collected from Regional Blood Transfusion Center in Casablanca and Blood Transfusion Center in El Jadida. The study protocol was in accordance with the Helsinki declaration and received an approval from the ethics Committee of the Faculty of Medicine of Rabat (N°17/20).

Serological testing
Serologic tests to ascertain the presence of the antibody against SARS-CoV-2 (IgG) were conducted at the Viral Hepatitis Laboratory of the Pasteur Institute of Morocco. We used Architect™ SARS-CoV-2 IgG chemiluminescence microparticle immunoassay (CMIA) (Abbott Park, Illinois, USA) to detect serum IgG Abs directed against the nucleocapsid protein of SARS-CoV-2. Interpretation of results was based on manufacturer's criteria: negative when the cut-off index (S/C) < 1.4 and positive when the cut-off index (S/C) ≥ 1.4.

Statistical Analysis
Data are presented as mean values (with corresponding standard errors of mean). Two-tailed Student's ttest or one-way ANOVA were used to analyze the differences between groups. Correlations between antibody index and age were assessed using Pearson's correlation coe cient. Statistical analyses were performed using GraphPad PRISM version 6.0e (GraphPad Software, San Diego, CA, USA).

Results
Among 14,000 blood donors screened in the rst wave, 94 individuals who tested positive for SARS-CoV-2-IgG, and were included in the study population as the rst-wave cohort. Among 1,986 blood donors in the second wave, 596 individuals were positive for SARS-CoV-2-IgG, and were included in the study population as the second-wave cohort.
The 94 COVID-19-recovered subjects in the rst wave had a mean age of 38 ± 10 years and sex ratio (male/female) of 1. The 596 COVID-19-recovered subjects in the second wave had a mean age of 36 ± 10 years and sex ratio (male/female) of 2.16. No signi cant difference was observed regarding age between these cohorts (p = 0.2325). However, signi cant difference was observed regarding sex between these cohorts (p = 0.0002). Antibody index analyses revealed that the second-wave cohort had an elevated humoral immunity relative to the rst-wave cohort (3.897 ± 0.079 vs. 2.842 ± 0.153, p < 0.0001, respectively) ( Fig. 2A).
We tested for associations of age and sex with antibody index among subjects in the second wave cohort. Notably, we found an age-related gradient in antibody levels (p = 0.01451) (Fig. 2B & Fig. 2C). Interestingly, SARS-CoV-2 antibody index was higher in individuals aged 45 years or above (Fig. 2B).
However, no signi cant difference was observed between men and woman regarding antibody index (p = 0.8629) (Fig. 2D).

Discussion
Herein, we report a comparative evaluation of humoral immune response in SARS-CoV-2-IgG positive blood donors covering two waves of infection over a period of more than 11 months. We found that antibody response was greater in the second than the rst wave. However, we are unable to assess the functionality of antibodies during the rst and second waves due to lack of virus neutralization assay.
However, the N protein is predicted to serve as a surrogate marker for the S protein-neutralizing antibody complex [10]. While all viral proteins are vulnerable to mutations that could impact diagnostic test performance, the S protein is under more selective pressure [2]. This atypical humoral immunity is particularly relevant in Morocco, where the second wave commenced around September 2020 and was probably linked to multiple distinct variants having accumulated mutations that differed from those in variants circulating during the rst wave. Indeed, the SARS-CoV-2 strains circulating during the early epidemic phase in Morocco are different to those circulating in the second wave. Analysis of Moroccan SARS-CoV-2 sequences from the rst wave clustered SARS-CoV-2 strains in clades G, B11, and A2 with the presence of amino acid change at D614G, which resembles strains seen in Asia, Europe, North America, Australia, and Africa, this indicating multiple SARS-CoV-2 introductions into Morocco [11][12][13]. Similarities are also evident with European strains seen at the beginning of the pandemic, and SARS-CoV-2 strains isolated in America and Africa later in the pandemic [14]. In addition, in Morocco, SARS-CoV-2 strains identi ed during December 2020 revealed an increased number of mutations relative to those identi ed in the rst wave [15,16]. This pattern appears to be in line with previous reports showing that viral genomes from the rst and second waves belong to different clades/lineages [17][18][19]. Moreover, several recent reports of reinfection, as indicated by viral sequence differences, clinical data and data on potential exposure, have raised critical questions about whether and how well a rst infection protects against reinfection [9,[17][18][19][20]. In addition, a relationship between a humoral immune response to SARS-CoV-2 infection and protection against reinfection with the identical SARS-CoV-2 strain has been shown in rhesus macaques, but has yet to be established in humans [21]. However, with the emergence of new variants more studies are needed to determine whether the SARS-CoV-2 variants re ect antigenic differences between strains circulating in the rst and second waves, or waning immunity against SARS-CoV-2 [17].
In this study, older age was associated with greater IgG responses to SARS-CoV-2 but gender did not affect this association. Previous studies showed that older age is associated with greater antibody production and that males consistently had greater antibodies levels [22,23].
In conclusion, our data revealed an important issue regarding antibody-mediated immune response against SARS-CoV-2 infection during the second wave. This issue may have arisen due to the dynamics of differences between circulating strains as the pandemic progressed and/or between speci c human genetic variants that contribute to inter-individual variability in serum immunoglobulin levels [24].
There are limitations associated with this study. The antibody response induced by COVID-19 tends to be linked to the severity of the disease. However, the disease severity could not be determined in the recovering subjects. The study was also limited by the lack of assessment of neutralizing antibody levels.
Further investigations are warranted to determine whether common or divergent factors are driving this drift in humoral immunity during the COVID-19 pandemic.

Declaration of Competing Interest
All authors declare that there are no con icts of interests.

Funding
This study was supported by Ministry of Health, Morocco.

None
Availability of data and material The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Not applicable
Ethics approval and consent to participate The study protocol was in accordance with the Helsinki declaration and received an approval from the ethics Committee of the Faculty of Medicine of Rabat (N°17/20). The need for informed consent was waived because this was an observational retrospective study, and all patient data were analyzed anonymously.

Consent for publication
All authors approved the nal version for publication.  Antibody index of seropositive subjects. A) Comparison between rst and second waves. Data are presented as mean and standard error of mean (SEM). B) Box and whiskers plot of antibody index with regard to age. The line crossing the box represents the mean. The whiskers extend to the minimal and maximal observed in each cohort. C) Age is associated with antibody responses to SARS-CoV-2. D) The graphic shows aligned dot plot of antibody index according to gender. Data are presented as mean ± SEM. Data were compared using Student's two-tailed t-test or one-way ANOVA.